WAVE Life Sciences - Stock Price History | WVE

Historical daily share price chart and data for WAVE Life Sciences since 2021 adjusted for splits. The latest closing stock price for WAVE Life Sciences as of September 27, 2021 is 6.16.
  • The all-time high WAVE Life Sciences stock closing price was 55.20 on September 24, 2018.
  • The WAVE Life Sciences 52-week high stock price is 12.17, which is 97.6% above the current share price.
  • The WAVE Life Sciences 52-week low stock price is 4.82, which is 21.8% below the current share price.
  • The average WAVE Life Sciences stock price for the last 52 weeks is 7.66.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
WAVE Life Sciences Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 9.3264 7.9800 19.5400 6.9400 7.8700 -1.81%
2019 28.8817 41.0100 47.9100 7.9900 8.0150 -80.93%
2018 43.6796 34.8000 55.2000 32.4500 42.0400 19.77%
2017 24.6697 26.2000 39.3500 15.2500 35.1000 34.23%
2016 21.4744 15.0700 39.5500 9.6000 26.1500 63.95%
2015 15.6804 16.0000 19.5800 13.0800 15.9500 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.313B $0.020B
WAVE Life Sciences Pte. Ltd. is a preclinical biopharmaceutical company. It designs, develops and commercializes nucleic acid therapeutic candidates for Huntington's disease, Duchenne muscular dystrophy and inflammatory bowel disease. Huntington's disease, the Company has programs targeting HTT SNP-1 and HTT SNP-2; DMD, targeting Exon 51 and in IBD, it is targeting SMAD7. The Company has late-stage discovery programs in epidermolysis bullosa simplex, in which it is targeting KRT14 SNP-1 and KRT14 SNP-2 and in DMD, it is focused on an additional DMD target, Activin Receptor type IIb. WAVE Life Sciences Pte. Ltd. is based in Singapore.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $132.971B 8.85
Bio-Rad Laboratories (BIO.B) United States $22.624B 48.22
QIAGEN (QGEN) Netherlands $12.001B 20.32
Biohaven Pharmaceutical Holding (BHVN) United States $8.691B 0.00
Emergent Biosolutions (EBS) United States $2.870B 6.92
Arcus Biosciences (RCUS) United States $2.690B 0.00
Myovant Sciences (MYOV) United Kingdom $2.182B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.045B 0.00
Zymeworks (ZYME) Canada $1.373B 0.00
Ambrx Biopharma (AMAM) United States $0.501B 0.00
SQZ Biotechnologies (SQZ) United States $0.442B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29